(Q35688209)

9 August 2017

1 reference

title

Gut peptides in the treatment of diabetes mellitus (English)

1 reference

9 August 2017

Torsten P Vahl

1

1 reference

PubMed ID

15013938

9 August 2017

David A D'Alessio

series ordinal

2

1 reference

PubMed ID

15013938

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

1 reference

9 August 2017

13

1 reference

9 August 2017

3

1 reference

9 August 2017

177-188

1 reference

Glucagon-like peptide-1 is a physiological incretin in rat

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: demonstration by a receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Interactions between insulin resistance and insulin secretion in the development of glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Attenuated GLP-1 secretion in obesity: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Hamster preproglucagon contains the sequence of glucagon and two related peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Gastric Inhibitory Polypeptide (GIP) Stimulated by Fat Ingestion in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Signal transduction of the GLP-1-receptor cloned from a human insulinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Interaction of glucagon-like peptide-I (7-37) and somatostatin-14 on signal transduction and proinsulin gene expression in beta TC-1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Functional GIP receptors in a hamster pancreatic beta cell line, In 111: Specific binding and biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

GIP biology and fat metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Gastric Inhibitory Polypeptide: Structure and Chromosomal Localization of the Human Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.3.177

10.1517/13543784.13.3.177

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15013938